0001564590-22-023497.txt : 20220617 0001564590-22-023497.hdr.sgml : 20220617 20220617090742 ACCESSION NUMBER: 0001564590-22-023497 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20220616 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20220617 DATE AS OF CHANGE: 20220617 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lyra Therapeutics, Inc. CENTRAL INDEX KEY: 0001327273 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39273 FILM NUMBER: 221022533 BUSINESS ADDRESS: STREET 1: 480 ARSENAL WAY CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-373-4600 MAIL ADDRESS: STREET 1: 480 ARSENAL WAY CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: 480 Biomedical, Inc. DATE OF NAME CHANGE: 20120927 FORMER COMPANY: FORMER CONFORMED NAME: Arsenal Vascular, Inc. DATE OF NAME CHANGE: 20110826 FORMER COMPANY: FORMER CONFORMED NAME: Arsenal Medical, Inc. DATE OF NAME CHANGE: 20090414 8-K 1 lyra-8k_20220616.htm 8-K lyra-8k_20220616.htm
false 0001327273 0001327273 2022-06-16 2022-06-16

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): June 16, 2022

 

LYRA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

001-39273

84-1700838

(State or other jurisdiction

of incorporation)

(Commission File Number)

(I.R.S. Employer

Identification No.)

 

 

 

480 Arsenal Way

Watertown, MA 02472

(Address of principal executive offices) (Zip Code)

(617) 393-4600

(Registrant’s telephone number, include area code)

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, $0.001 par value per share

 

LYRA

 

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 


 

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

On June 16, 2022, Lyra Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Meeting”). A total of 22,339,206 shares of common stock were present online or represented by proxy at the Meeting, representing approximately 70.19% of the Company’s outstanding common stock as of the April 22, 2022 record date. The following are the voting results for the proposals considered and voted upon at the Meeting, all of which were described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 27, 2022.

Item 1 - Election of three Class II Directors to serve until the 2025 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified.

 

NOMINEE

Votes

FOR

Votes

WITHHELD

Broker

Non-Votes

Michael Altman

19,683,305

189,235

2,466,666

C. Ann Merrifield

19,683,656

188,884

2,466,666

Harlan Waksal, M.D.

19,845,106

27,434

2,466,666

Item 2 - Ratification of the appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022.

 

 

 

 

 

Votes

FOR

Votes

AGAINST

Votes

ABSTAINED

Broker

Non-Votes

22,297,210

25,501

16,495

0

Based on the foregoing votes, Michael Altman, C. Ann Merrifield and Harlan Waksal, M.D. were elected as Class II Directors and Item 2 was approved.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

 

 

 

 

 

 

LYRA THERAPEUTICS, INC.

 

 

 

 

Date: June 17, 2022

 

 

 

By:

 

/s/ Jason Cavalier

 

 

 

 

 

 

Jason Cavalier

 

 

 

 

 

 

Chief Financial Officer

 

 

 

 

 

 EX-101.SCH 2 lyra-20220616.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 lyra-20220616_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Entity File Number Entity File Number Entity Incorporation State Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name EX-101.PRE 4 lyra-20220616_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
Jun. 16, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 16, 2022
Entity Registrant Name LYRA THERAPEUTICS, INC.
Entity Central Index Key 0001327273
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity File Number 001-39273
Entity Incorporation State Country Code DE
Entity Tax Identification Number 84-1700838
Entity Address, Address Line One 480 Arsenal Way
Entity Address, City or Town Watertown
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02472
City Area Code 617
Local Phone Number 393-4600
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.001 par value per share
Trading Symbol LYRA
Security Exchange Name NASDAQ
XML 6 lyra-8k_20220616_htm.xml IDEA: XBRL DOCUMENT 0001327273 2022-06-16 2022-06-16 false 0001327273 8-K 2022-06-16 LYRA THERAPEUTICS, INC. DE 001-39273 84-1700838 480 Arsenal Way Watertown MA 02472 617 393-4600 false false false false Common Stock, $0.001 par value per share LYRA NASDAQ true false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( /1(T50'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #T2-%4$?E+P^X K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M:L,P#(=?9?B>*'^@ 9/ZTK'3!H,5-G8SLMJ:Q8FQ-9*^_9RL31G; ^QHZ>=/ MGT M>HE#H.

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

-8?20$3;8T.P6BP^0"X99K>]9!:GH_ 0 / ( \ !X;"]W;W)K8F]O:RYX;6R-49:EL@9OTDUL(,BDBN0-2TN'+#4$QJ8:@+W+IGD^ MR[S!H)>+D6M#V743&4K&& 3L@!W".?W.NU:=,.$>'?)WH?NW ZT\!O1X 5OH M7*M4Q_-+)+S$P,9M2XK.%7HR#'9 C.4?>-N)_#3[U"-L]A]&A!1ZE@MAA92X MW^CYC6@\@2P/73>TFH=>Y!L/?P&HT=S8\?M_P! M4$L#!!0 ( /1(T50D'INBK0 /@! : >&PO7W)E;',O=V]R:V)O M;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% M 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\ I%NTBB[.XS!/:A>LXEF& M!KS2O6H0DBBZ0=@S9)[NF:*'3^ 5!+ P04 " #T2-%499!YDAD! #/ P $P %M#;VYT96YT7U1Y M<&5S72YX;6RMDTU.PS 0A:\295LE+BQ8H*8;8 M=< %C3QJK_I-G6M+;,T[: M2J 2%85-K'C>O,^>EZS>CQ&PZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)* MM9-;$/?+Y8-0P1-XJBA[E.O5,[1R;ZEXZ7D;3?!-FI6.5Z*U .EK M>MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ M!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO. M\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0 ( /1(T50'04UB@0 +$ M 0 " 0 !D;V-0&UL4$L! A0#% M @ ]$C15!'Y2\/N *P( !$ ( !KP &1O8U!R;W!S M+V-O&UL4$L! A0#% @ ]$C15)E&PO=V]R:W-H965T&UL4$L! A0#% @ ]$C15)^@&_"Q @ X@P T M ( !D P 'AL+W-T>6QE&PO=V]R:V)O M;VLN>&UL4$L! A0#% @ ]$C15"0>FZ*M ^ $ !H M ( !P1$ 'AL+U]R96QS+W=O9(9 0 SP, !, ( !IA( %M#;VYT96YT7U1Y ><&5S72YX;6Q02P4& D "0 ^ @ \!, end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://lyratherapeutics.com/20220616/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports lyra-8k_20220616.htm lyra-20220616.xsd lyra-20220616_lab.xml lyra-20220616_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "lyra-8k_20220616.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "lyra-8k_20220616.htm" ] }, "labelLink": { "local": [ "lyra-20220616_lab.xml" ] }, "presentationLink": { "local": [ "lyra-20220616_pre.xml" ] }, "schema": { "local": [ "lyra-20220616.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "lyra", "nsuri": "http://lyratherapeutics.com/20220616", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "lyra-8k_20220616.htm", "contextRef": "C_0001327273_20220616_20220616", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://lyratherapeutics.com/20220616/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "lyra-8k_20220616.htm", "contextRef": "C_0001327273_20220616_20220616", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://lyratherapeutics.com/20220616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://lyratherapeutics.com/20220616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://lyratherapeutics.com/20220616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://lyratherapeutics.com/20220616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://lyratherapeutics.com/20220616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://lyratherapeutics.com/20220616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://lyratherapeutics.com/20220616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://lyratherapeutics.com/20220616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://lyratherapeutics.com/20220616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://lyratherapeutics.com/20220616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://lyratherapeutics.com/20220616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://lyratherapeutics.com/20220616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://lyratherapeutics.com/20220616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://lyratherapeutics.com/20220616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://lyratherapeutics.com/20220616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://lyratherapeutics.com/20220616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://lyratherapeutics.com/20220616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://lyratherapeutics.com/20220616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://lyratherapeutics.com/20220616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://lyratherapeutics.com/20220616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://lyratherapeutics.com/20220616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://lyratherapeutics.com/20220616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://lyratherapeutics.com/20220616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 13 0001564590-22-023497-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-22-023497-xbrl.zip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